SynthesisBMC infectious diseases2026
Incidence of kelch13 and Pfmdr1 gene mutations associated with antimalarial drug resistance in Plasmodium falciparum isolates from Ethiopia: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing prevalence of drug-resistant Plasmodium parasites, driven by factors including genetic mutations, intensifies the challenge of malaria eradication. This meta-analysis focused on the genetic component of resistance, specifically evaluating mutations in the kelch13 (R622I, P441L and A675V) and Pfmdr1 (Y184F and D1246Y) genes within Ethiopian Plasmodium falciparum strains.
methodsA systematic literature search was conducted across the PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, and Google Scholar databases. Eligible studies included primary data on the prevalence of kelch13 and Pfmdr1 gene mutations in Plasmodium falciparum isolates from Ethiopia. Two reviewers independently conducted study selection, data extraction, and quality assessment. Heterogeneity was evaluated using the I² statistic, and a random-effects model was utilized to pool prevalence estimates with 95% confidence intervals (CI). Subgroup and sensitivity analyses were performed to explore sources of heterogeneity. Publication bias was assessed using funnel plots and Eggers test. All analyses were carried out using STATA software version 16.
resultsA total of fifteen studies were reviewed and analyzed, comprising 11,269 samples and 5,521 positive cases of Plasmodium falciparum. Pooled prevalence of kelch13 gene mutations at R622I, A675V, and P441L was 11%, 1% and 0% respectively. Pooled prevalence of Pfmdr1 gene mutations at D1246Y and Y184F was 6% and 77%, respectively. Subgroup analysis revealed this resistance marker has significantly increased over time, rising from 66% (2007–2014) to a concerning 91% (2015–2025).
conclusionsWhile most resistance markers remain rare or absent, the significant rise in the Pfmdr1 Y184F mutation highlights a growing concern regarding antimalarial drug resistance in Ethiopia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.